Coronavirus Update: Regeneron Gets Warp Speed Funding, Conflict Slowing Moderna's Progress

Plus: GSK agrees new vaccine collaboration

 
• By Scrip Team
  
Generate a summary of this article
Listen to this article
Beta

Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.

Brazil
Brazil's president Jair Bolsonaro, seen here earlier this month in maskless crowds, has tested positive for COVID-19. Brazil has the second-highest number of cases and deaths in the world, after the US.

Regeneron Pharmaceuticals, Inc. has secured $450m from the US government to build out the supply of REGN-COV2, an antibody cocktail in Phase III development for the prevention of COVID-19 infection. The company announced the funding from the Biomedical Advanced Research and Development Authority (BARDA) on 7 July under Operation Warp Speed, a program intended to speed the development of vaccines and treatments to address the health crisis.

The funding will help Regeneron build up the supply of REGN-COV2 before the antibody cocktail has even been shown to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains